Your browser doesn't support javascript.
Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022.
Stefanelli, Paola; Trentini, Filippo; Petrone, Daniele; Mammone, Alessia; Ambrosio, Luigina; Manica, Mattia; Guzzetta, Giorgio; d'Andrea, Valeria; Marziano, Valentina; Zardini, Agnese; Molina Grane', Carla; Ajelli, Marco; Di Martino, Angela; Riccardo, Flavia; Bella, Antonino; Sane Schepisi, Monica; Maraglino, Francesco; Poletti, Piero; Palamara, Anna Teresa; Brusaferro, Silvio; Rezza, Giovanni; Pezzotti, Patrizio; Merler, Stefano.
  • Stefanelli P; Istituto Superiore di Sanità, Rome, Italy.
  • Trentini F; Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milan, Italy.
  • Petrone D; Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.
  • Mammone A; Istituto Superiore di Sanità, Rome, Italy.
  • Ambrosio L; Health Prevention Directorate, Ministry of Health, Rome, Italy.
  • Manica M; Istituto Superiore di Sanità, Rome, Italy.
  • Guzzetta G; Epilab-JRU, FEM-FBK Joint Research Unit, Trento, Italy.
  • d'Andrea V; Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.
  • Marziano V; Epilab-JRU, FEM-FBK Joint Research Unit, Trento, Italy.
  • Zardini A; Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.
  • Molina Grane' C; Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.
  • Ajelli M; Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.
  • Di Martino A; Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.
  • Riccardo F; University of Trento, Trento, Italy.
  • Bella A; Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.
  • Sane Schepisi M; Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, United States.
  • Maraglino F; Istituto Superiore di Sanità, Rome, Italy.
  • Poletti P; Istituto Superiore di Sanità, Rome, Italy.
  • Palamara AT; Istituto Superiore di Sanità, Rome, Italy.
  • Brusaferro S; Health Prevention Directorate, Ministry of Health, Rome, Italy.
  • Rezza G; Health Prevention Directorate, Ministry of Health, Rome, Italy.
  • Pezzotti P; Epilab-JRU, FEM-FBK Joint Research Unit, Trento, Italy.
  • Merler S; Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.
Euro Surveill ; 27(45)2022 11.
Artículo en Inglés | MEDLINE | ID: covidwho-2117835
ABSTRACT
BackgroundThe SARS-CoV-2 variant of concern Omicron was first detected in Italy in November 2021.AimTo comprehensively describe Omicron spread in Italy in the 2 subsequent months and its impact on the overall SARS-CoV-2 circulation at population level.MethodsWe analyse data from four genomic surveys conducted across the country between December 2021 and January 2022. Combining genomic sequencing results with epidemiological records collated by the National Integrated Surveillance System, the Omicron reproductive number and exponential growth rate are estimated, as well as SARS-CoV-2 transmissibility.ResultsOmicron became dominant in Italy less than 1 month after its first detection, representing on 3 January 76.9-80.2% of notified SARS-CoV-2 infections, with a doubling time of 2.7-3.3 days. As of 17 January 2022, Delta variant represented < 6% of cases. During the Omicron expansion in December 2021, the estimated mean net reproduction numbers respectively rose from 1.15 to a maximum of 1.83 for symptomatic cases and from 1.14 to 1.36 for hospitalised cases, while remaining relatively stable, between 0.93 and 1.21, for cases needing intensive care. Despite a reduction in relative proportion, Delta infections increased in absolute terms throughout December contributing to an increase in hospitalisations. A significant reproduction numbers' decline was found after mid-January, with average estimates dropping below 1 between 10 and 16 January 2022.ConclusionEstimates suggest a marked growth advantage of Omicron compared with Delta variant, but lower disease severity at population level possibly due to residual immunity against severe outcomes acquired from vaccination and prior infection.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Estudio observacional / Estudio pronóstico Tópicos: Vacunas / Variantes Límite: Humanos Idioma: Inglés Asunto de la revista: Enfermedades Transmisibles Año: 2022 Tipo del documento: Artículo País de afiliación: 1560-7917.ES.2022.27.45.2200125

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Estudio observacional / Estudio pronóstico Tópicos: Vacunas / Variantes Límite: Humanos Idioma: Inglés Asunto de la revista: Enfermedades Transmisibles Año: 2022 Tipo del documento: Artículo País de afiliación: 1560-7917.ES.2022.27.45.2200125